Jinhai Medical Technology H1 revenue jumps on China strength

Jinhai Medical Technology

27/08/2026 09:50

Overview
China-based medical device maker's half-year revenue more than doubled year-over-year
Company narrowed net loss for the period compared to last year
Loss per share improved to S$0.08 from S$0.20 a year earlier

Outlook
Company did not provide specific financial guidance or outlook for future periods in the press release

Result Drivers
CHINA MEDICAL PRODUCTS – Revenue from minimally invasive surgery solutions and medical products more than quadrupled, mainly due to business growth in China

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
S$34 mln
 

Reuters Recommended Reads
Aug 25 - China's Weigao H1 profit falls 23% as price drops, competition hit margins
Aug 24 - China's Shanghai INT Medical Instruments H1 revenue jumps on acquisitions
Aug 24 - China's Peijia Medical H1 revenue jumps on transcatheter valve therapeutics growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)